



I'm not a robot 
reCAPTCHA



Open

Current NCCN Guidelines for Post-operative Therapy



NCCN guideline(Version 3.2011)

All including SCC



*R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.
†Adverse factors include: inadequate mediastinal lymph node dissection, extracapsular spread, multiple positive hilar nodes, close margins.

Nccn guidelines esophageal cancer 2021 pdf. Nccn guidelines esophageal cancer 2020. Nccn guidelines esophageal cancer 2021. Nccn guidelines esophageal cancer. Nccn guidelines esophageal cancer 2019.

Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced squamous cell carcinoma of the esophagus and esophagogastric junction: first results of the study Checkmate 649. In all randomized patients, the FC was 0.80 (95% CI, 0.68-0.94; p = .0002). The Nivolumab-containing scheme also resulted in an improvement in the objective response rate (ORR) on chemotherapy alone, by 60% (95% CI, 55%-65%) vs 45% (95%, 40%-50%), respectively (p = .0002).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66